EW Edwards Lifesciences Corporation Common Stock
NYSE · Health Care · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 4, 2026
$85.15
· of 52w range
· above low
· to high
$72.3052w low
$96.2952w high
Market Cap (MRQ)
$49.10B
P/E (TTM)
48.9
EPS (TTM)
$1.74
Revenue (TTM)
$6.51B
your badges
52W Range
$72–$96
Analyst Rating
BUY
Price Target
$101
P/E
48.9
ROE
9.5%
Net Profit Margin
15.4%
Your badge strip is empty — pin a metric anywhere on this page.
EW Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$85.15
Market Cap (MRQ)
$49.10B
P/E (TTM)
48.9
EPS (TTM)
$1.74
Revenue (TTM)
$6.51B
ROE (TTM)
9.5%
Debt/Equity (MRQ)
0.1
52W Range
$72–$96
EW Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
Stock splits
| Ex-date | Split | Type |
|---|---|---|
| June 1, 2020 | 3-for-1 | Forward |
| Dec. 14, 2015 | 2-for-1 | Forward |
| May 28, 2010 | 2-for-1 | Forward |
About Edwards Lifesciences Corporation Common Stock Company overview from Wikipedia
Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in tissue heart valves and transcatheter technologies for the treatment of structural heart disease. The company has manufacturing facilities at the Irvine headquarters, as well as in Draper, Utah; Costa Rica; Singapore; and Limerick, Ireland. The company is also constructing a manufacturing plant in Moncada, near Valencia, Spain, with a €150 million investment. Production is scheduled to begin in 2027.
History
Edwards Lifesciences was originally founded by electrical engineer Miles "Lowell" Edwards in 1958, a graduate of Oregon State University. Edwards invented the first medically proven and adopted artificial heart valve. Dr. Albert Starr, a surgeon at the Oregon Health and Sciences University, is credited as the first to successfully implant the Starr-Edwards mitral valve in a patient in 1960. As a result of the successful heart implant, Edwards established manufacturing in Santa Ana, California the same year to continue his research in pulmonary devices.
Edwards' valves are still in operation today. An early patient lived a record 48 years with the implant before requiring a replacement.
Edwards was acquired by Baxter in 1985. It was spun off from Baxter in 2000.
In 2017, Edwards completed the acquisition of Valtech Cardio for $340 million. Also in 2017, Edwards acquired Harpoon Medical of Baltimore, Maryland for $100 million. Harpoon, founded in 2013, developed a minimally invasive heart surgery product for mitral valve repair to treat degenerative mitral regurgitation. At the time of the acquisition, the product was not available on any market.
On April 18, 2019, Edwards completed the acquisition of CAS Medical Systems of Branford, Connecticut for ~$100 million.
Edwards Sapien 3 and Sapien 3 Ultra Transcatheter Heart Valve systems were FDA-approved for the treatment of patients at low risk for death or major complications associated with open-heart surgery on August 16, 2019. These products are used to treat patients with severe aortic stenosis without utilizing open-heart surgery.
In 2020, Edwards co-sponsored the Virtual ISPOR-FDA Summit centered on patient preference information in medical device regulatory decisions.
In December 2021, the FDA approved the SAPIEN 3 transcatheter valve in combination with the Alterra adaptive prestent for the treatment of severe pulmonary regurgitation.
In February 2024, the FDA approved Edwards' EVOQUE tricuspid valve replacement system, the first transcatheter therapy approved in the United States for the treatment of tricuspid regurgitation. In May 2024, Edwards launched the SAPIEN 3 Ultra RESILIA valve in Europe.
In June 2024, the company received FDA approval for a new implant designed to manage heart failure issues, called the Cordella pulmonary artery sensor.
In July 2024, Edwards made agreements with Affluent Medical for an equity stake, IP licensing and an exclusive option to acquire its Kephalios subsidiary. The same month, Edwards announced it would acquire Innovalve Bio Medical for approximately $300 million, and JenaValve Technology and Endotronix for $1.2 billion.
In August 2024, Edwards acquired JC Medical from Genesis MedTech, gaining its J-Valve transcatheter aortic valve replacement system for the treatment of aortic regurgitation.
In 2023, Edwards announced that its critical care business unit would be spun off into a separate entity. In June 2024 Edwards instead agreed to sell the unit to BD for $4.2 billion. The sale closed on September 3, 2024.
In May 2025, the FDA approved the SAPIEN 3 platform, including the SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA valves, for the treatment of severe aortic stenosis in asymptomatic patients, marking the first FDA approval of TAVR therapy for this patient population.
In September 2025, Edwards completed the full acquisition of heart failure monitoring company Vectorious Medical Technologies.
In January 2026, the FDA approved the SAPIEN M3 mitral valve replacement system, the first transcatheter mitral valve replacement therapy using a transseptal approach to receive FDA approval for the treatment of mitral regurgitation.
Business segments
Prior to September 2024, its products were categorized into four areas: surgical valve technologies, transcatheter heart valves, transcatheter mitral and tricuspid therapies, and critical care. In September 2024, Edwards completed the sale of its Critical Care product group to BD. Since September 2024, its products are categorized into four areas: surgical valve technologies, transcatheter heart valves, transcatheter mitral and tricuspid therapies, and implantable heart failure management (IHFM).
Transcatheter Heart Valve
The company's SAPIEN family of transcatheter aortic heart valves is made of bovine pericardial tissue mounted within a balloon-expandable, cobalt-chromium frame and is deployed via catheter. Edwards introduced the transcatheter heart valve replacement procedure to U.S. patients unable to undergo open-heart surgery with FDA approval of the SAPIEN transcatheter valve in 2011. The indication was expanded in November 2012 to include patients at a high risk for death or serious complications associated with open-heart surgery. In 2021, the FDA cleared Edwards’ SAPIEN 3 transcatheter valve with the Alterra adaptive prestent for pulmonic heart valve replacement. In May 2024, Edwards launched the SAPIEN 3 Ultra RESILIA valve in Europe.
Transcatheter Mitral and Tricuspid Therapies
The Transcatheter Mitral and Tricuspid Therapies business segment develops transcatheter heart valve repair and replacement technologies to treat mitral and tricuspid valve diseases. In September 2022, the FDA approved Edwards' PASCAL Precision transcatheter valve repair system for the treatment of degenerative mitral regurgitation.
Surgical
The Surgical business segment involves the use of Edwards' RESILIA tissue technology, developed to help limit valve calcification. Edwards estimates that more than 450,000 patients around the world have either undergone SAVR or TAVR with an Edwards RESILIA valve.
Critical Care
Before its sale, the Critical Care business segment included pulmonary artery catheters, disposable pressure transducers and advanced hemodynamic monitoring systems. The portfolio also included a line of balloon catheter-based vascular products, surgical clips and inserts. In 2023, it was announced that the critical care business unit was to be spun off into its own entity, however in 2024 the critical care department was purchased by BD for $4.2 billion.
Organizational culture
Edwards Lifesciences Foundation
The Edwards Lifesciences Foundation launched in 2014 and supports programs designed to treat underserved people to reduce heart valve disease.
Since the initiative launched in 2014, Edwards and its foundation have contributed more than $100 million in financial and technology donations through "Every Heartbeat Matters" (EHM), reaching over 4 million underserved structural heart patients globally.
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
sectorHealth Care
industryHealth Care
employees16,000
countryUS
10-Year Performance Revenue, net income, margins and EPS trends
Revenue$6.07B2016-12-31 → 2025-12-31
EPS$1.832016-12-31 → 2025-12-31
Free Cash Flow$1.33B2016-12-31 → 2025-12-31
Net margin15.4%2023-12-31 → 2025-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | EW | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E (TTM) | 48.95Y avg ≈35.1 | ≈35.1 | 31.0 | Overvalued | |
| P/S (TTM) | 7.55Y avg ≈10.2 | ≈10.2 | 5.0 | Overvalued | |
| P/B (MRQ) | 4.65Y avg ≈7.5 | ≈7.5 | 5.0 | Fair value | |
| EV / EBITDA (TTM) | 28.15Y avg ≈30.5 | ≈30.5 | 27.0 | Overvalued | |
| Price / FCF (TTM) | 34.25Y avg ≈72.6 | ≈72.6 | · | · | |
| Price / Cash Flow (TTM) | 28.55Y avg ≈49.3 | ≈49.3 | 26.4 | Overvalued | |
| EV / Revenue (TTM) | 7.05Y avg ≈9.8 | ≈9.8 | · | · | |
| EV / FCF (TTM) | 31.75Y avg ≈69.1 | ≈69.1 | · | · | |
| Price / Tangible Book (MRQ) | 5.35Y avg ≈10.1 | ≈10.1 | · | · | |
| PEG Ratio | ≈6.9 | · | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | EW | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Gross Margin (TTM) | 77.8%5Y avg ≈78.1% | ≈78.1% | 65.9% | Top tier | |
| Operating Margin (TTM) | 22.3%5Y avg ≈27.3% | ≈27.3% | 24.8% | Top tier | |
| EBITDA Margin (TTM) | 24.8%5Y avg ≈29.9% | ≈29.9% | 29.5% | In line | |
| Pretax Margin (TTM) | 21.8%5Y avg ≈28.3% | ≈28.3% | 24.0% | Top tier | |
| Net Profit Margin (TTM) | 15.4%5Y avg ≈39.3% | ≈39.3% | 17.8% | Weak | |
| ROA (TTM) | 7.3%5Y avg ≈20.4% | ≈20.4% | 7.9% | In line | |
| ROE (TTM) | 9.5%5Y avg ≈27.7% | ≈27.7% | 15.9% | Weak | |
| ROIC | 9.6%5Y avg ≈17.3% | ≈17.3% | 11.5% | Weak |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | EW | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Debt / Equity (MRQ) | 0.15Y avg ≈0.1 | ≈0.1 | 0.6 | Low debt | |
| Current Ratio (MRQ) | 4.55Y avg ≈3.5 | ≈3.5 | 1.6 | Strong liquidity | |
| Quick Ratio (MRQ) | 3.35Y avg ≈2.3 | ≈2.3 | 0.9 | Strong liquidity | |
| Long-Term Debt / Equity (MRQ) | 0.15Y avg ≈0.1 | ≈0.1 | 0.6 | Low debt |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | EW | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue YoY | 11.6%5Y avg ≈7.4% | ≈7.4% | · | · | |
| Revenue CAGR 3Y | 10.8%5Y avg ≈5.5% | ≈5.5% | · | · | |
| Revenue CAGR 5Y | 6.7% | · | · | · | |
| EPS YoY | -73.7%5Y avg ≈41.8% | ≈41.8% | · | · | |
| Net Income YoY | -74.3%5Y avg ≈29.2% | ≈29.2% | · | · | |
| EPS CAGR 3Y | -9.1%5Y avg ≈18.3% | ≈18.3% | · | · | |
| EPS CAGR 5Y | 7.1% | · | · | · | |
| Net Income CAGR 3Y | -11.0% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | EW | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 0.55Y avg ≈0.6 | ≈0.6 | 0.5 | Weak | |
| Inventory Turnover | 1.25Y avg ≈1.3 | ≈1.3 | 2.4 | Weak | |
| Receivables Turnover | 9.65Y avg ≈8.8 | ≈8.8 | 6.8 | Top tier | |
| Revenue / Employee | ≈$379.2K | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
2.6%
Next Report
Oct 28, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Jul 22, 2026 | $0.78 | $0.76 | 2.3% |
| March 31, 2026 | $0.78 | $0.75 | 4.2% | |
| Dec. 31, 2025 | $0.58 | $0.64 | -8.8% | |
| Sept. 30, 2025 | $0.67 | $0.61 | 9.6% | |
| June 30, 2025 | $0.67 | $0.64 | 4.4% | |
| March 31, 2025 | $0.64 | $0.61 | 4.1% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.07B | $5.44B | $5.01B | $4.46B | $5.23B | $4.39B | $4.35B | $3.72B | $3.44B | $2.96B | $2.49B | $2.32B | |
| Cost of Revenue | $1.33B | $1.12B | $978M | $724M | $1.25B | $1.08B | $1.11B | $939M | $875M | $797M | $617M | $626M | |
| Gross Profit | $4.73B | $4.32B | $4.03B | $3.74B | $3.98B | $3.31B | $3.23B | $2.78B | $2.56B | $2.17B | $1.88B | $1.70B | |
| R&D Expense | $1.08B | $1.05B | $963M | $844M | $903M | $761M | $753M | $622M | $553M | $442M | $383M | $346M | |
| SG&A Expense | $2.09B | $1.79B | $1.58B | $1.36B | $1.49B | $1.23B | $1.24B | $1.09B | $991M | $905M | $851M | $858M | |
| Operating Income | $1.26B | $1.38B | $1.31B | $1.50B | $1.69B | $898M | $1.15B | $748M | $1.09B | $751M | · | · | |
| Interest Expense | · | · | $18M | $19M | $18M | $16M | $21M | $30M | $23M | $19M | $17M | $17M | |
| Interest Income | $169M | $120M | $67M | $36M | $17M | $23M | $32M | $32M | $20M | $11M | $8M | $6M | |
| Other Non-op | $7M | $69M | $14M | $5M | $13M | $12M | $8M | $4M | $-1M | $-5M | $-4M | $-8M | |
| Pretax Income | $1.27B | $1.55B | $1.37B | $1.52B | $1.70B | $917M | $1.17B | $761M | $1.03B | $738M | $622M | $1.14B | |
| Income Tax | $217M | $152M | $152M | $196M | $199M | $93M | $120M | $39M | $451M | $168M | $128M | $333M | |
| Net Income | $1.07B | $4.17B | $1.40B | $1.52B | $1.50B | · | · | · | · | · | · | · | |
| EPS (Basic) | $1.84 | $6.98 | $2.31 | $2.46 | $2.41 | $1.32 | $1.68 | $1.15 | $2.77 | $2.67 | $2.30 | $3.81 | |
| EPS (Diluted) | $1.83 | $6.97 | $2.30 | $2.44 | $2.38 | $1.30 | $1.64 | $1.13 | $2.70 | $2.61 | $2.25 | $3.74 | |
| Shares (Basic) | 584,800,000 | 597,700,000 | 606,700,000 | 619,000,000 | 623,300,000 | 622,600,000 | 624,800,000 | 627,600,000 | 210,900,000 | 213,000,000 | 215,500,000 | 213,000,000 | |
| Shares (Diluted) | 585,800,000 | 599,300,000 | 609,400,000 | 624,200,000 | 631,200,000 | 631,900,000 | 636,700,000 | 640,900,000 | 215,900,000 | 217,800,000 | 220,300,000 | 217,000,000 | |
| EBITDA | $1.42B | $1.53B | $1.68B | $1.89B | $1.83B | $1.00B | $1.24B | $826M | $82M | $71M | $66M | $69M |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.94B | $3.05B | $1.13B | $769M | $863M | $1.18B | $1.18B | $714M | $818M | $930M | $718M | $654M | |
| Short-term Investments | $1.29B | $931M | $500M | $446M | $604M | $219M | $338M | $242M | $519M | $341M | $506M | $785M | |
| Receivables | $660M | $609M | $772M | $643M | $582M | $515M | $544M | $457M | $439M | $366M | $315M | $288M | |
| Inventory | $1.13B | $1.09B | $904M | $876M | $727M | $802M | $641M | $607M | $555M | $397M | $340M | $297M | |
| Prepaid Expense | $135M | $121M | $129M | $110M | $85M | $75M | $59M | $54M | $61M | $46M | $45M | $49M | |
| Other Current Assets | $339M | $348M | $225M | $196M | $237M | $208M | $168M | $132M | $117M | $112M | $66M | $122M | |
| Current Assets | $6.74B | $6.29B | $4.04B | $3.10B | $3.18B | $3.09B | $2.98B | $2.29B | $2.55B | $2.24B | $2.05B | $2.23B | |
| PP&E (Net) | $1.81B | $1.69B | $1.59B | $1.63B | $1.55B | $1.40B | $1.06B | $868M | $680M | $580M | $482M | $443M | |
| PP&E (Gross) | $2.66B | $2.48B | $2.29B | $2.38B | $2.20B | $1.99B | $1.57B | $1.32B | $1.09B | $961M | $854M | $808M | |
| Accum. Depreciation | $850M | $794M | $699M | $750M | $655M | $598M | $512M | $455M | $412M | $381M | $372M | $365M | |
| Goodwill | $1.77B | $1.78B | $1.15B | $1.06B | $1.17B | $1.17B | $1.17B | $1.11B | $1.13B | $626M | $628M | $376M | |
| Intangibles | $1.13B | $1.18B | $399M | $285M | $324M | $331M | $336M | $343M | $468M | $205M | $205M | $23M | |
| Other Non-current Assets | $730M | $722M | $463M | $299M | $111M | $120M | $102M | $34M | $109M | $123M | $132M | $49M | |
| Total Assets | $13.70B | $13.06B | $9.36B | $8.29B | $8.50B | $7.24B | $6.49B | $5.32B | $5.67B | $4.51B | $4.06B | $3.52B | |
| Accounts Payable | $228M | $197M | $187M | $202M | $204M | $196M | $180M | $134M | $117M | $97M | $64M | $58M | |
| Current Liabilities | $1.81B | $1.51B | $1.20B | $1.02B | $1.03B | $894M | $902M | $877M | $1.42B | $532M | $476M | $426M | |
| Capital Leases | $83M | $79M | $65M | $70M | $69M | $73M | $59M | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $37M | · | · | · | · | · | |
| Other Non-current Liabilities | $362M | $373M | $251M | $218M | $267M | $252M | $203M | $150M | $147M | $115M | $285M | $113M | |
| Total Liabilities | $3.36B | $2.99B | $2.64B | $2.49B | $2.67B | $2.66B | · | · | · | · | · | · | |
| Long-term Debt | · | · | · | · | · | · | · | $594M | $1.04B | $822M | · | · | |
| Total Debt | $598M | $598M | $597M | $596M | $596M | $595M | $594M | $594M | $1.04B | $822M | $600M | $598M | |
| Common Stock | $659M | $655M | $650M | $646M | $642M | $636M | $218M | $215M | $212M | $243M | $239M | $129M | |
| Retained Earnings | $14.24B | $13.17B | $8.99B | $7.59B | $6.07B | $4.57B | $3.74B | $2.69B | $1.96B | $3.91B | $3.34B | $2.84B | |
| Treasury Stock | $7.09B | $6.19B | $5.02B | $4.14B | $2.42B | $1.90B | $1.28B | $1.02B | $252M | $2.50B | $1.84B | $1.56B | |
| AOCI | $-238M | $-244M | $-243M | $-255M | $-158M | $-161M | $-156M | $-138M | $-133M | $-198M | $-183M | $-101M | |
| Stockholders' Equity | $10.34B | $10.00B | $6.65B | $5.81B | $5.84B | $4.57B | $4.15B | $3.14B | $2.96B | $2.62B | $2.50B | $2.19B | |
| Liabilities + Equity | $13.70B | $13.06B | $9.36B | $8.29B | $8.50B | $7.24B | $6.49B | $5.32B | $5.67B | $4.51B | $4.06B | $3.52B | |
| Shares Outstanding | 580,700,000 | 654,800,000 | 650,500,000 | 646,300,000 | 642,000,000 | 636,400,000 | 218,100,000 | 207,700,000 | 209,700,000 | 211,600,000 | 215,400,000 | 107,800,000 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $157M | $155M | $145M | $140M | $135M | $107M | $89M | $77M | $82M | $71M | $66M | $69M | |
| Stock-based Comp | $158M | $162M | $139M | $127M | $109M | $93M | $81M | $71M | $62M | $57M | $50M | $48M | |
| Deferred Tax | $-66M | $-163M | $-242M | $-262M | $-44M | $-52M | $10M | $-21M | $27M | $-24M | $-16M | $-67M | |
| Amort. of Intangibles | $8M | $6M | $2M | $2M | $8M | $5M | $5M | $2M | $8M | $8M | $7M | $8M | |
| Restructuring | $13M | $33M | · | · | · | · | · | · | · | · | $0 | $0 | |
| Other Non-cash | $273M | $-3.79B | $-529M | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $1.60B | $542M | $896M | $1.22B | $1.73B | $1.05B | $1.18B | $927M | $1.00B | $704M | $550M | $1.02B | |
| CapEx | $260M | $252M | $253M | $245M | $326M | $407M | $254M | $239M | $168M | $176M | $103M | $83M | |
| Investing Cash Flow | $-713M | $2.31B | $174M | $252M | $-1.72B | $-531M | $-596M | $77M | $-647M | $-212M | $-316M | · | |
| Debt Issued | · | · | $0 | $0 | $5M | $16M | $19M | $688M | $995M | $254M | $31M | $226M | |
| Net Debt Issued | · | · | $0 | $0 | $5M | $16M | $19M | $688M | $995M | $254M | $31M | $226M | |
| Stock Repurchased | $893M | $1.16B | $880M | $1.73B | $513M | $625M | $263M | $796M | $763M | $662M | $280M | $301M | |
| Net Stock Activity | $-893M | $-1.16B | $-880M | $-1.73B | $-513M | $-625M | $-263M | $-796M | $-763M | $-662M | $-280M | $-301M | |
| Financing Cash Flow | $-957M | $-983M | $-711M | $-1.58B | $-356M | $-487M | $-116M | $-1.10B | $-473M | $-268M | $-159M | · | |
| Net Change in Cash | $-119M | $1.91B | $375M | $-95M | $-333M | $16M | $468M | $-104M | $-112M | $212M | $65M | $233M | |
| Taxes Paid | $490M | $1.20B | $470M | · | · | · | · | · | · | · | · | $275M | |
| Free Cash Flow | $1.33B | $290M | $643M | $974M | $1.41B | $647M | $925M | $688M | $833M | $528M | $447M | $939M | |
| Levered FCF | · | · | $627M | $957M | $1.39B | $633M | $906M | $660M | $820M | $513M | $433M | $927M |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 78.0% | 79.5% | 77.0% | 79.9% | 76.1% | 75.4% | 74.4% | 74.8% | 74.5% | 73.1% | 75.2% | 73.1% | |
| Operating Margin | 20.8% | 25.4% | 25.6% | 32.5% | 32.3% | 20.5% | 26.4% | 20.1% | · | · | · | · | |
| Net Margin | 17.7% | 76.8% | 23.4% | · | · | · | · | · | · | · | · | · | |
| Pretax Margin | 21.0% | 28.5% | 26.6% | 32.8% | 32.5% | 20.9% | 26.8% | 20.4% | 30.1% | 24.9% | 25.0% | 49.2% | |
| EBITDA Margin | 23.4% | 28.2% | 28.0% | 35.1% | 34.9% | 22.9% | 28.4% | 22.2% | 2.4% | 2.4% | 2.6% | 2.9% | |
| ROA | 8.0% | 37.2% | 15.9% | · | · | · | · | · | · | · | · | · | |
| ROE | 10.6% | 50.1% | 22.5% | · | · | · | · | · | · | · | · | · | |
| ROIC | 9.6% | 11.7% | 18.5% | 23.5% | 23.2% | 15.6% | 21.7% | 19.0% | · | · | · | · |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.7 | 4.2 | 3.4 | 3.0 | 3.1 | 3.5 | 3.3 | 2.6 | 1.8 | 4.2 | 4.3 | 5.3 | |
| Quick Ratio | 2.7 | 3.0 | 2.0 | 1.8 | 2.0 | 2.1 | 2.3 | 1.6 | 1.3 | 3.1 | 3.2 | 4.0 | |
| Debt / Equity | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.4 | 0.3 | 0.2 | 0.3 | |
| LT Debt / Equity | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.1 | 0.3 | 0.2 | 0.3 | |
| Interest Coverage | · | · | 87.2 | 91.1 | 91.9 | 56.8 | 55.4 | 25.0 | · | · | · | · |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.5 | 0.7 | 0.6 | 0.7 | 0.6 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | |
| Inventory Turnover | 1.2 | 1.1 | 1.4 | 1.3 | 1.6 | 1.5 | 1.8 | 1.6 | 1.8 | 2.2 | 1.9 | 2.1 | |
| Receivables Turnover | 9.6 | 7.9 | 8.5 | 8.8 | 9.5 | 8.3 | 8.7 | 8.3 | 8.7 | 8.7 | 8.3 | 7.9 |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $17.80 | $16.99 | $11.06 | $9.55 | $9.35 | $7.33 | $19.84 | $15.12 | $14.10 | $12.38 | $11.62 | $20.33 | |
| Revenue / Share | $10.36 | $9.08 | $9.85 | $8.62 | $8.29 | $6.94 | $20.49 | $17.43 | $15.91 | $13.61 | $11.32 | $21.41 | |
| Cash Flow / Share | $2.72 | $0.90 | $1.47 | $1.95 | $2.74 | $1.67 | $5.56 | $4.34 | $4.63 | $3.23 | $2.50 | $9.42 | |
| Cash / Share | $5.06 | $5.17 | $1.90 | $1.26 | $1.38 | $1.90 | $5.64 | $3.44 | $3.90 | $4.40 | $3.34 | $6.06 | |
| EPS (TTM) | $1.83 | $6.97 | $2.30 | $2.44 | $2.38 | $1.30 | $1.64 | $1.13 | $2.70 | $2.61 | $2.25 | $3.74 |
Growth Rates
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 11.6% | 8.6% | 12.2% | -14.7% | 19.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 10.8% | 1.3% | 4.5% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 6.7% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -73.7% | 203.0% | -5.7% | 2.5% | 83.1% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | -9.1% | 43.1% | 20.9% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 7.1% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -74.3% | 197.7% | -7.8% | 1.2% | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | -11.0% | 40.6% | · | · | · | · | · | · | · | · | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $6.07B | $5.44B | $5.01B | $4.46B | $5.23B | $4.39B | $4.35B | $3.72B | $3.44B | $2.96B | $2.49B | $2.32B | |
| Net Income TTM | $1.07B | $4.17B | $1.40B | $1.52B | $1.50B | $235M | $235M | $235M | $235M | $235M | $235M | $235M | |
| Market Cap | $49.50B | $43.57B | $45.83B | $45.39B | $80.85B | $56.95B | $16.26B | $10.60B | $7.88B | $6.61B | $5.67B | $2.29B | |
| Enterprise Value | $45.88B | $40.20B | $44.79B | $44.77B | $79.98B | $56.15B | $15.34B | $10.24B | $7.58B | $6.16B | $5.05B | $1.45B | |
| P/E | 46.6 | 10.6 | 33.2 | 30.6 | 54.4 | 70.2 | 47.4 | 45.2 | 13.9 | 12.0 | 11.7 | 5.7 | |
| P/S | 8.2 | 8.0 | 9.1 | 10.2 | 15.5 | 13.0 | 3.7 | 2.8 | 2.3 | 2.2 | 2.3 | 1.0 | |
| P/B | 4.8 | 4.4 | 6.9 | 7.8 | 13.9 | 12.5 | 3.9 | 3.4 | 2.7 | 2.5 | 2.3 | 1.0 | |
| P / Tangible Book | 6.7 | 6.2 | 9.0 | 10.2 | 18.6 | 18.6 | · | · | · | · | · | · | |
| P / Cash Flow | 31.0 | 80.4 | 51.2 | 37.3 | 46.7 | 54.0 | 13.8 | 11.4 | 7.9 | 9.4 | 10.3 | 2.2 | |
| P / FCF | 37.1 | 150.3 | 71.3 | 46.6 | 57.5 | 88.0 | 17.6 | 15.4 | 9.5 | 12.5 | 12.7 | 2.4 | |
| EV / EBITDA | 32.3 | 26.2 | 26.7 | 23.7 | 43.8 | 55.9 | 12.4 | 12.4 | 92.5 | 86.5 | 76.7 | 21.1 | |
| EV / FCF | 34.4 | 138.7 | 69.7 | 46.0 | 56.9 | 86.7 | 16.6 | 14.9 | 9.1 | 11.7 | 11.3 | 1.5 | |
| EV / Revenue | 7.6 | 7.4 | 8.9 | 10.0 | 15.3 | 12.8 | 3.5 | 2.8 | 2.2 | 2.1 | 2.0 | 0.6 | |
| Earnings Yield | 2.1% | 9.4% | 3.0% | 3.3% | 1.8% | 1.4% | 2.1% | 2.2% | 7.2% | 8.4% | 8.6% | 17.6% |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.74B | $1.65B | $1.57B | $1.55B | $1.53B | $1.41B | $1.39B | $1.35B | $1.37B | $1.33B | $1.01B | $1.24B | $1.28B | $1.22B | $430M | $1.32B | |
| Cost of Revenue | $392M | $363M | $343M | $345M | $344M | $302M | $292M | $263M | $276M | $287M | $141M | $251M | $257M | $330M | $-99M | $254M | |
| Gross Profit | $1.35B | $1.29B | $1.23B | $1.21B | $1.19B | $1.11B | $1.09B | $1.09B | $1.09B | $1.04B | $870M | $993M | $1.03B | $992M | $529M | $1.07B | |
| R&D Expense | $279M | $263M | $268M | $281M | $276M | $255M | $271M | $253M | $272M | $257M | $215M | $243M | $244M | $261M | $131M | $234M | |
| SG&A Expense | $561M | $522M | $603M | $515M | $502M | $466M | $492M | $421M | $448M | $428M | $354M | $382M | $410M | $436M | $201M | $377M | |
| Operating Income | $513M | $478M | $151M | $307M | $411M | $395M | $313M | $351M | $366M | $349M | $291M | $366M | $264M | $388M | $198M | $402M | |
| Interest Income | $30M | $34M | · | · | $37M | $36M | · | · | · | · | · | · | · | · | · | · | |
| Other Non-op | $17M | $72M | $3M | $3M | $-1M | $3M | $33M | $28M | $2M | $6M | $3M | $7M | $2M | $2M | $6M | $-2M | |
| Pretax Income | $520M | $459M | $90M | $348M | $400M | $434M | $390M | $403M | $384M | $371M | $311M | $388M | $275M | $399M | $211M | $407M | |
| Income Tax | $278M | $78M | $26M | $56M | $64M | $70M | $45M | $41M | $20M | $46M | $21M | $53M | $21M | $58M | $11M | $64M | |
| Net Income | $242M | $381M | $91M | $291M | $333M | $358M | $386M | $3.07B | $366M | $352M | $370M | $385M | $307M | $340M | $398M | $344M | |
| EPS (Basic) | $0.42 | $0.66 | $0.16 | $0.50 | $0.57 | $0.61 | $0.65 | $5.14 | $0.61 | $0.58 | $0.61 | $0.63 | $0.51 | $0.56 | $0.66 | $0.55 | |
| EPS (Diluted) | $0.42 | $0.66 | $0.16 | $0.50 | $0.56 | $0.61 | $0.65 | $5.13 | $0.61 | $0.58 | $0.61 | $0.63 | $0.50 | $0.56 | $0.65 | $0.55 | |
| Shares (Basic) | 576,400,000 | 579,200,000 | · | 584,700,000 | 587,000,000 | 586,900,000 | · | 597,200,000 | 602,100,000 | 601,600,000 | · | 607,000,000 | 606,900,000 | 607,500,000 | · | 619,800,000 | |
| Shares (Diluted) | 577,600,000 | 580,700,000 | · | 585,700,000 | 587,900,000 | 587,800,000 | · | 598,100,000 | 604,300,000 | 604,100,000 | · | 609,500,000 | 610,300,000 | 610,900,000 | · | 624,500,000 | |
| EBITDA | $513M | $518M | · | $307M | $411M | $431M | · | $351M | $369M | $426M | · | $418M | $327M | $424M | · | $402M |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.91B | $2.45B | $2.94B | $2.69B | $3.27B | $3.14B | $3.05B | $3.68B | $1.64B | $1.22B | · | $1.41B | $1.04B | $872M | · | $1.25B | |
| Short-term Investments | $1.35B | $1.23B | $1.29B | $1.16B | $789M | $758M | $931M | $770M | $345M | $473M | · | $454M | $467M | $382M | · | $491M | |
| Receivables | $770M | $776M | $660M | $693M | $697M | $669M | $609M | $716M | $778M | $818M | · | $740M | $754M | $718M | · | $618M | |
| Inventory | $1.13B | $1.12B | $1.13B | $1.14B | $1.14B | $1.11B | $1.09B | $1.10B | $1.02B | $1.21B | · | $1.03B | $980M | $914M | · | $758M | |
| Prepaid Expense | $119M | $136M | $135M | $125M | $110M | $111M | $121M | $115M | $110M | $138M | · | $133M | $123M | $119M | · | $88M | |
| Other Current Assets | $360M | $330M | $339M | $323M | $314M | $304M | $348M | $231M | $252M | $251M | · | $236M | $217M | $190M | · | $268M | |
| Current Assets | $6.82B | $6.23B | $6.74B | $6.36B | $6.58B | $6.21B | $6.29B | $6.73B | $4.52B | $4.17B | · | $4.07B | $3.65B | $3.26B | · | $3.51B | |
| PP&E (Net) | $1.84B | $1.82B | $1.81B | $1.74B | $1.73B | $1.70B | $1.69B | $1.68B | $1.64B | $1.77B | · | $1.68B | $1.66B | $1.65B | · | $1.57B | |
| PP&E (Gross) | · | · | $2.66B | · | · | · | $2.48B | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $850M | · | · | · | $794M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $1.95B | $1.82B | $1.77B | $1.77B | $1.78B | $1.78B | $1.78B | $1.61B | $1.15B | $1.25B | $1.15B | $1.30B | $1.30B | $1.31B | $1.06B | $1.16B | |
| Intangibles | $1.38B | $1.23B | $1.13B | $1.13B | $1.17B | $1.17B | $1.18B | $956M | $417M | $447M | · | $430M | $431M | $447M | · | $266M | |
| Other Non-current Assets | $616M | $739M | $730M | $785M | $743M | $743M | $722M | $684M | $790M | $768M | · | $447M | $412M | $294M | · | $316M | |
| Total Assets | $13.87B | $13.32B | $13.70B | $13.27B | $13.49B | $13.02B | $13.06B | $12.97B | $10.10B | $9.74B | · | $9.37B | $9.00B | $8.65B | · | $8.64B | |
| Accounts Payable | $210M | $181M | $228M | $165M | $162M | $172M | $197M | $173M | $186M | $212M | · | $191M | $193M | $181M | · | $155M | |
| Current Liabilities | $1.51B | $1.41B | $1.81B | $1.59B | $1.40B | $1.39B | $1.51B | $1.94B | $1.22B | $1.11B | · | $1.24B | $1.16B | $1.08B | · | $918M | |
| Capital Leases | $82M | $80M | $83M | $75M | $79M | $78M | $79M | $85M | $74M | $77M | · | $70M | $64M | $66M | · | $67M | |
| Other Non-current Liabilities | $382M | $351M | $362M | $363M | $379M | $358M | $373M | $323M | $257M | $266M | · | $240M | $243M | $260M | · | $221M | |
| Total Liabilities | $3.14B | $2.99B | $3.36B | $3.07B | $2.88B | $2.83B | $2.99B | $3.36B | $2.59B | $2.55B | · | $2.64B | $2.56B | $2.59B | · | $2.42B | |
| Total Debt | $599M | $598M | · | $598M | $598M | $598M | · | $598M | $597M | $597M | · | $597M | $597M | $596M | · | $596M | |
| Common Stock | $662M | $660M | $659M | $658M | $658M | $656M | $655M | $654M | $654M | $652M | · | $650M | $649M | $647M | · | $646M | |
| Retained Earnings | $14.86B | $14.62B | $14.24B | $14.15B | $13.86B | $13.53B | $13.17B | $12.78B | $9.71B | $9.34B | · | $8.62B | $8.24B | $7.93B | · | $7.19B | |
| Treasury Stock | $7.67B | $7.51B | $7.09B | $7.05B | $6.46B | $6.45B | $6.19B | $6.09B | $5.18B | $5.02B | · | $4.58B | $4.40B | $4.39B | · | $3.28B | |
| AOCI | $-215M | $-221M | $-238M | $-250M | $-264M | $-254M | $-244M | $-252M | $-220M | $-233M | · | $-250M | $-256M | $-255M | · | $-256M | |
| Stockholders' Equity | $10.62B | $10.33B | $10.34B | $10.21B | $10.55B | $10.13B | $10.00B | $9.55B | $7.44B | $7.12B | · | $6.66B | $6.38B | $5.98B | · | $6.22B | |
| Liabilities + Equity | $13.87B | $13.32B | $13.70B | $13.27B | $13.49B | $13.02B | $13.06B | $12.97B | $10.10B | $9.74B | · | $9.37B | $9.00B | $8.65B | · | $8.64B | |
| Shares Outstanding | 576,600,000 | 577,000,000 | 580,700,000 | 580,700,000 | 587,900,000 | 586,200,000 | 588,600,000 | 589,800,000 | 602,300,000 | 602,400,000 | 650,500,000 | 606,500,000 | 607,900,000 | 606,000,000 | 646,300,000 | 619,400,000 |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $43M | $41M | $43M | $39M | $38M | $37M | $43M | $34M | $40M | $38M | $37M | $37M | $36M | $35M | $35M | $35M | |
| Stock-based Comp | $42M | $45M | $39M | $41M | $38M | $40M | $32M | $42M | $44M | $45M | $30M | $33M | $37M | $39M | $28M | $30M | |
| Restructuring | · | · | $5M | $100.0K | · | · | $0 | $33M | · | · | · | $0 | · | · | · | · | |
| Other Non-cash | · | $-423M | · | · | · | $-154M | · | · | · | $-488M | · | · | · | · | · | · | |
| Operating Cash Flow | $652M | $44M | $451M | $574M | $290M | $280M | $-128M | $352M | $372M | $-54M | $137M | $412M | $34M | $314M | $283M | $310M | |
| CapEx | $67M | $65M | $97M | $58M | $49M | $56M | $50M | $52M | $85M | $65M | $88M | $55M | $48M | $62M | $69M | $60M | |
| Investing Cash Flow | $-193M | $-93M | $-198M | $-428M | $-172M | $85M | $-577M | $2.70B | $125M | $63M | $14M | $89M | $70M | $500.0K | $95M | $-202M | |
| Debt Issued | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| Stock Repurchased | $153M | $422M | $41M | $589M | $6M | $259M | $100M | $901M | $158M | $200.0K | $448M | $174M | $8M | $249M | $866M | $100M | |
| Net Stock Activity | · | $-422M | · | · | · | $-259M | · | · | · | $-200.0K | · | · | · | $-249M | · | · | |
| Financing Cash Flow | $-300.0K | $-451M | $-11M | $-740M | $53M | $-258M | $29M | $-977M | $-97M | $62M | $-413M | $-143M | $52M | $-207M | $-838M | $-70M | |
| Net Change in Cash | $462M | $-492M | $245M | $-595M | $141M | $90M | $-625M | $2.03B | $429M | $81M | $-266M | $366M | $171M | $104M | $-479M | $49M | |
| Free Cash Flow | · | $-21M | · | · | · | $224M | · | · | · | $-119M | · | · | · | $253M | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 77.5% | 78.0% | · | 77.8% | 77.5% | 78.6% | · | 80.6% | 79.4% | 75.9% | · | 76.3% | 77.6% | 77.4% | · | 80.8% | |
| Operating Margin | 29.5% | 29.0% | · | 19.8% | 26.8% | 28.0% | · | 25.9% | 26.6% | 24.2% | · | 28.2% | 21.4% | 26.6% | · | 30.5% | |
| Net Margin | 13.9% | 23.1% | · | 18.7% | 21.8% | 25.3% | · | 226.7% | 26.4% | 22.0% | · | 26.0% | 20.1% | · | · | · | |
| Pretax Margin | 29.9% | 27.8% | · | 22.4% | 26.1% | 30.7% | · | 29.7% | 27.9% | 25.6% | · | 29.7% | 22.1% | 27.3% | · | 30.9% | |
| EBITDA Margin | 29.5% | 31.4% | · | 19.8% | 26.8% | 30.5% | · | 25.9% | 26.6% | 26.7% | · | 28.2% | 21.4% | 29.0% | · | 30.5% | |
| ROA | 1.8% | 2.9% | · | 2.2% | 2.8% | 3.1% | · | 27.5% | 3.8% | 3.8% | · | 4.3% | 3.5% | · | · | · | |
| ROE | 2.3% | 3.7% | · | 2.9% | 3.7% | 4.2% | · | 37.9% | 5.3% | 5.4% | · | 6.0% | 5.0% | · | · | · | |
| ROIC | 2.1% | 3.6% | · | 2.4% | 3.1% | 3.1% | · | 3.1% | 4.3% | 4.3% | · | 5.0% | 4.2% | 5.1% | · | 5.0% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.5 | 4.4 | · | 4.0 | 4.7 | 4.5 | · | 3.5 | 3.7 | 3.8 | · | 3.3 | 3.2 | 3.0 | · | 3.8 | |
| Quick Ratio | 3.3 | 3.2 | · | 2.9 | 3.4 | 3.3 | · | 2.7 | 2.3 | 2.3 | · | 2.1 | 2.0 | 1.8 | · | 2.6 | |
| Debt / Equity | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| LT Debt / Equity | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 |
Efficiency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| Inventory Turnover | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.2 | 0.3 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.3 | |
| Receivables Turnover | 2.4 | 2.3 | · | 2.2 | 2.1 | 1.9 | · | 1.9 | 1.8 | 2.1 | · | 2.2 | 2.2 | 2.2 | · | 2.2 |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $18.41 | $17.90 | · | $17.57 | $17.94 | $17.28 | · | $16.18 | $12.35 | $11.82 | · | $10.98 | $10.49 | $9.86 | · | $10.04 | |
| Revenue / Share | $3.01 | $2.84 | · | $2.65 | $2.61 | $2.40 | · | $2.26 | $2.29 | $2.65 | · | $2.43 | $2.51 | $2.39 | · | $2.11 | |
| Cash Flow / Share | · | $0.08 | · | · | · | $0.48 | · | · | · | $-0.09 | · | · | · | $0.51 | · | · | |
| Cash / Share | $5.04 | $4.24 | · | $4.62 | $5.57 | $5.36 | · | $6.23 | $2.73 | $2.03 | · | $2.33 | $1.72 | $1.44 | · | $2.01 | |
| EPS (TTM) | $1.74 | $1.88 | · | $2.32 | $6.95 | $7.00 | · | $6.93 | $2.43 | $2.32 | · | $2.34 | $2.26 | $2.41 | · | $2.31 |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $6.51B | $6.30B | · | $5.88B | $5.69B | $5.52B | · | $5.07B | $4.95B | $4.86B | · | $4.17B | $4.25B | $4.34B | · | $5.36B | |
| Net Income TTM | $1.00B | $1.10B | · | $1.37B | $4.15B | $4.18B | · | $4.16B | $1.47B | $1.41B | · | $1.43B | $1.39B | $1.49B | · | · | |
| Market Cap | $52.16B | $46.21B | · | $45.16B | $45.98B | $42.49B | · | $38.92B | $55.63B | $57.57B | · | $42.02B | $57.34B | $50.13B | · | $51.18B | |
| Enterprise Value | $48.51B | $43.13B | · | $41.92B | $42.52B | $39.19B | · | $35.07B | $54.24B | $56.46B | · | $40.75B | $56.43B | $49.48B | · | $50.04B | |
| P/E | 52.0 | 42.6 | · | 33.5 | 11.3 | 10.4 | · | 9.5 | 38.0 | 41.2 | · | 29.6 | 41.7 | 34.3 | · | 35.8 | |
| P/S | 8.0 | 7.3 | · | 7.7 | 8.1 | 7.7 | · | 7.7 | 11.2 | 11.8 | · | 10.1 | 13.5 | 11.5 | · | 9.5 | |
| P/B | 4.9 | 4.5 | · | 4.4 | 4.4 | 4.2 | · | 4.1 | 7.5 | 8.1 | · | 6.3 | 9.0 | 8.4 | · | 8.2 | |
| P / Tangible Book | 7.2 | 6.3 | · | 6.2 | 6.1 | 5.9 | · | 5.6 | 9.5 | 10.6 | · | 8.5 | 12.3 | 11.9 | · | 10.7 | |
| P / Cash Flow | · | 1054.9 | · | · | · | 151.5 | · | · | · | -1076.0 | · | · | · | 159.6 | · | · | |
| EV / Revenue | 7.4 | 6.8 | · | 7.1 | 7.5 | 7.1 | · | 6.9 | 10.9 | 11.6 | · | 9.8 | 13.3 | 11.4 | · | 9.3 | |
| Earnings Yield | 1.9% | 2.4% | · | 3.0% | 8.9% | 9.7% | · | 10.5% | 2.6% | 2.4% | · | 3.4% | 2.4% | 2.9% | · | 2.8% |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $6.07B | $5.44B | $5.01B | $4.46B | $5.23B |
| Gross Margin % | 78.0% | 79.5% | 77.0% | 79.9% | 76.1% |
| Operating Margin % | 20.8% | 25.4% | 25.6% | 32.5% | 32.3% |
| Net Income | $1.07B | $4.17B | $1.40B | $1.52B | $1.50B |
| Diluted EPS | $1.83 | $6.97 | $2.30 | $2.44 | $2.38 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Debt / Equity | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Current Ratio | 3.7 | 4.2 | 3.4 | 3.0 | 3.1 |
| Quick Ratio | 2.7 | 3.0 | 2.0 | 1.8 | 2.0 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | $1.33B | $290M | $643M | $974M | $1.41B |
Institutional owners (13F) 1,432 filers · $52.4B total · As of Sept. 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
1,432
Value held
$52.4B
New positions
155
Exited positions
97
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 155 (+6 vs prior Q) | 97 (-12 vs prior Q) | 471 (+23 vs prior Q) | 469 (+12 vs prior Q) | +13.8M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| VANGUARD GROUP INC | $5,974,271,834 | 70,079,435 | 11.40% | Shares |
| BlackRock, Inc. | $5,318,092,039 | 58,789,433 | 10.15% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $3,402,739,018 | 37,615,952 | 6.50% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $2,389,175,425 | 26,411,402 | 4.56% | Shares |
| STATE STREET CORP | $2,381,082,692 | 26,321,940 | 4.55% | Shares |
| JPMORGAN CHASE & CO | $2,077,369,996 | 22,783,175 | 3.97% | Shares |
| WELLINGTON MANAGEMENT GROUP LLP | $1,522,257,896 | 16,827,967 | 2.91% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $1,390,906,696 | 15,437,251 | 2.66% | Shares |
| Bank of New York Mellon Corp | $1,274,082,304 | 14,084,483 | 2.43% | Shares |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | $1,176,248,067 | 13,002,965 | 2.25% | Shares |
| Ninety One UK Ltd | $1,116,050,276 | 12,337,502 | 2.13% | Shares |
| Aristotle Capital Management, LLC | $783,906,442 | 8,665,712 | 1.50% | Shares |
| FMR LLC | $763,115,873 | 8,435,949 | 1.46% | Shares |
| NORGES BANK | $757,492,410 | 8,373,783 | 1.45% | Shares |
| ALLIANCEBERNSTEIN L.P. | $693,526,113 | 8,660,416 | 1.32% | Shares |
| BROWN ADVISORY INC | $666,327,162 | 7,365,987 | 1.27% | Shares |
| BANK OF AMERICA CORP /DE/ | $605,396,715 | 6,692,424 | 1.16% | Shares |
| Artisan Partners Limited Partnership | $599,361,052 | 6,625,703 | 1.14% | Shares |
| MORGAN STANLEY | $573,459,576 | 6,339,368 | 1.09% | Shares |
| DEUTSCHE BANK AG\ | $516,552,291 | 5,710,284 | 0.99% | Shares |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $513,572,538 | 5,677,344 | 0.98% | Shares |
| NORTHERN TRUST CORP | $513,019,376 | 5,671,229 | 0.98% | Shares |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $437,088,491 | 5,458,148 | 0.83% | Shares |
| WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST | $434,208,000 | 4,800,000 | 0.83% | Shares |
| GOLDMAN SACHS GROUP INC | $411,512,754 | 4,549,113 | 0.79% | Shares |
| Legal & General Group Plc | $389,088,546 | 4,301,222 | 0.74% | Shares |
| CITADEL ADVISORS LLC | $361,652,295 | 3,997,925 | 0.69% | Shares |
| Invesco Ltd. | $359,806,234 | 3,977,518 | 0.69% | Shares |
| DIMENSIONAL FUND ADVISORS LP | $334,928,288 | 3,702,299 | 0.64% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $334,071,856 | 3,693,034 | 0.64% | Shares |
| MILLENNIUM MANAGEMENT LLC | $324,280,556 | 3,584,795 | 0.62% | Shares |
| ROYAL BANK OF CANADA | $316,740,000 | 3,501,447 | 0.60% | Shares |
| PRIMECAP MANAGEMENT CO/CA/ | $308,314,004 | 3,408,291 | 0.59% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $292,399,738 | 3,232,365 | 0.56% | Shares |
| Holocene Advisors, LP | $283,979,721 | 3,139,285 | 0.54% | Shares |
| Nuveen, LLC | $267,803,860 | 2,960,468 | 0.51% | Shares |
| NEUBERGER BERMAN GROUP LLC | $261,237,879 | 2,886,953 | 0.50% | Shares |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $250,776,107 | 2,772,232 | 0.48% | Shares |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $238,277,000 | 2,634,054 | 0.45% | Shares |
| Amundi | $233,363,816 | 2,579,748 | 0.45% | Shares |
| Mirova US LLC | $229,802,865 | 2,540,381 | 0.44% | Shares |
| Allspring Global Investments Holdings, LLC | $228,999,539 | 2,489,396 | 0.44% | Shares |
| RAYMOND JAMES FINANCIAL INC | $219,553,940 | 2,427,083 | 0.42% | Shares |
| UBS Group AG | $212,640,342 | 2,350,656 | 0.41% | Shares |
| Russell Investments Group, Ltd. | $207,120,205 | 2,288,745 | 0.40% | Shares |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $175,696,355 | 1,942,132 | 0.34% | Shares |
| SEI INVESTMENTS CO | $171,883,685 | 1,900,137 | 0.33% | Shares |
| Assenagon Asset Management S.A. | $163,997,286 | 1,812,926 | 0.31% | Shares |
| Point72 Asset Management, L.P. | $160,486,895 | 1,774,120 | 0.31% | Shares |
| NORDEA INVESTMENT MANAGEMENT AB | $147,126,018 | 1,629,844 | 0.28% | Shares |
Activists & 5%+ owners 1 position
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Undisclosed reporting person | April 5, 2001 | · | Initial filing | Board campaign | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 48 insiders · 20 officers · 8 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Bernard J Zovighian | CEO | July 27, 2026 S | 8,916 | 0 | 8 | $-6,996,971 |
| Theodora Mistras | CVP, Chief Financial Officer | July 9, 2026 A | 99,920 | 0 | 0 | $0 |
| Thomas M Abate | CVP, CFO | May 14, 2013 A | 43,047 | 0 | 0 | $0 |
| Wayne Markowitz | CVP, JAPAC | Sept. 14, 2026 F | 19,371 | 0 | 5 | $-1,042,352 |
| Andrew M. Dahl | SVP, Corporate Controller | Sept. 13, 2026 F | 14,615 | 0 | 2 | $-98,430 |
| Daniel J. Lippis | CVP, TAVR | Sept. 11, 2026 M | 40,034 | 0 | 13 | $-871,621 |
| Daveen Chopra | CVP, TMTT, Surgical & IHFM | Sept. 11, 2026 F | 43,926 | 0 | 4 | $-3,190,031 |
| Annette Bruls | CVP, EMEACLA | Aug. 28, 2026 S | 17,984 | 0 | 1 | $-237,907 |
| Carlyn D Solomon | CVP, Critical Care & Vascular | Oct. 28, 2014 M | 31,154 | 0 | 0 | $0 |
| Christine Z Mccauley | CVP, Human Resources | May 13, 2013 F | 4,035 | 0 | 0 | $0 |
| Paul C Redmond | CVP, Global Operations | May 13, 2013 S | 12,534 | 0 | 0 | $0 |
| Bruce P Garren | CVP, Public Affairs/Special Co | May 13, 2013 F | 56,071 | 0 | 0 | $0 |
| John H Kehl JR | CVP, Strategy & Corp Dev | May 7, 2013 F | 101,767 | 0 | 0 | $0 |
| Robert C Reindl | CVP, H.R. and Communications | July 27, 2012 M | 1,124 | 0 | 0 | $0 |
| Aimee S Weisner | CVP, General Counsel | May 9, 2012 A | 1,675 | 0 | 0 | $0 |
| Corinne H Nevinny | CVP & Pres., Global Ops | May 13, 2010 A | 16,687 | 0 | 0 | $0 |
| Anita Bessler | CVP | Aug. 31, 2007 S | 29,410 | 0 | 0 | $0 |
| John Alexander Martin | CVP, North America | May 10, 2007 A | 15,300 | 0 | 0 | $0 |
| Stuart L Foster | CVP, Critical Care / Vascular | May 10, 2007 A | 24,604 | 0 | 0 | $0 |
| Randel William Woodgrift | Corp VP, Manufacturing Ops | Aug. 4, 2005 M | 3,349 | 0 | 0 | $0 |
| John T Cardis | Director | Aug. 10, 2016 S | 91,458 | 0 | 0 | $0 |
| Barbara J Mcneil | Director | Feb. 4, 2016 S | 46,454 | 0 | 0 | $0 |
| Robert Alexander Ingram | Director | May 15, 2015 A | 32,367 | 0 | 0 | $0 |
| Michael R Bowlin | Director | Nov. 14, 2014 M | 81,751 | 0 | 0 | $0 |
| David E I Pyott | Director | May 9, 2014 A | 53,582 | 0 | 0 | $0 |
| NEAL PHILIP M | Director | Aug. 12, 2008 M | 27,333 | 0 | 0 | $0 |
| Vernon R Loucks JR | Director | May 9, 2008 A | 24,133 | 0 | 0 | $0 |
| Donald E Bobo JR | · | May 27, 2026 S | 98,611 | 0 | 12 | $-11,153,294 |
| Scott B. Ullem | · | May 11, 2026 M | 46,740 | 0 | 7 | $-3,875,008 |
| Leslie C. Davis | · | May 8, 2026 A | 9,834 | 0 | 0 | $0 |
| Ramona Sequeira | · | May 8, 2026 A | 6,779 | 0 | 0 | $0 |
| David T Feinberg | · | May 8, 2026 A | 9,087 | 0 | 0 | $0 |
| Kieran Gallahue | · | May 8, 2026 A | 4,315 | 0 | 0 | $0 |
| Nicholas J Valeriani | · | May 8, 2026 A | 84,423 | 0 | 0 | $0 |
| Heisz Leslie Stone | · | May 8, 2026 A | 34,199 | 0 | 1 | $-218,117 |
| Steven R Loranger | · | May 8, 2026 A | 8,997 | 0 | 0 | $0 |
| Paul A Laviolette | · | May 8, 2026 A | 17,552 | 0 | 0 | $0 |
| Larry L Wood | · | Aug. 18, 2025 M | 206,900 | 0 | 0 | $0 |
| Catherine M. Szyman | · | Sept. 3, 2024 F | 81,287 | 0 | 0 | $0 |
| Jean-Luc M Lemercier | · | July 7, 2024 F | 184,686 | 0 | 0 | $0 |
| Robert W.A. Sellers | · | May 11, 2024 F | 17,081 | 0 | 0 | $0 |
| Michael A Mussallem | · | May 2, 2024 M | 4,486 | 0 | 0 | $0 |
| Martha H. Marsh | · | May 12, 2023 A | 31,880 | 0 | 0 | $0 |
| Huimin Wang | · | July 8, 2022 M | 99,381 | 0 | 0 | $0 |
| William J Link PHD | · | May 8, 2020 A | 11,349 | 0 | 0 | $0 |
| Wesley W Von Schack | · | Aug. 1, 2019 S | 8,000 | 0 | 0 | $0 |
| Patrick B Verguet | · | May 31, 2017 M | 129,137 | 0 | 0 | $0 |
| Randall J Nelson | · | Sept. 30, 2003 A | · | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 128 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| IHI · iShares Trust | 4.43% | 1,622,151 SH | Sept. 11, 2026 | Daily |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 1.73% | 1,827 NS | July 31, 2026 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1.63% | 167,084 SH | Oct. 2, 2026 | Daily |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1.55% | 12,485 NS | July 31, 2026 | N-PORT |
| VOT · VANGUARD INDEX FUNDS | 1.14% | 4,411,246 SH | Aug. 19, 2026 | Daily |
| CVAR · ETF Opportunities Trust | 0.90% | 4,502 NS | July 31, 2026 | N-PORT |
| JOET · Virtus ETF Trust II | 0.81% | 22,947 NS | July 31, 2026 | N-PORT |
| IYH · iShares Trust | 0.80% | 333,769 SH | Sept. 11, 2026 | Daily |
| NULV · Nushares ETF Trust | 0.78% | 199,212 NS | July 31, 2026 | N-PORT |
| SDG · iShares Trust | 0.77% | 14,866 SH | Sept. 11, 2026 | Daily |
| VHT · VANGUARD WORLD FUND | 0.77% | 1,733,147 SH | Aug. 19, 2026 | Daily |
| NULC · Nushares ETF Trust | 0.75% | 6,147 NS | July 31, 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0.72% | 274,258 NS | July 31, 2026 | N-PORT |
| IMCG · iShares Trust | 0.67% | 307,122 SH | Sept. 11, 2026 | Daily |
| IXJ · iShares Trust | 0.63% | 303,150 SH | Sept. 11, 2026 | Daily |
| JGLO · J.P. Morgan Exchange-Traded Fund Tr… | 0.58% | 451,454 NS | July 31, 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 0.57% | 11,330 NS | July 31, 2026 | N-PORT |
| HUSV · First Trust Exchange-Traded Fund III | 0.55% | 4,726 NS | July 31, 2026 | N-PORT |
| NULG · Nushares ETF Trust | 0.52% | 160,328 NS | July 31, 2026 | N-PORT |
| SUSA · iShares Trust | 0.50% | 233,488 SH | Sept. 11, 2026 | Daily |
| VO · VANGUARD INDEX FUNDS | 0.50% | 12,477,902 SH | Aug. 19, 2026 | Daily |
| IWS · iShares Trust | 0.49% | 851,606 SH | Sept. 11, 2026 | Daily |
| HELO · J.P. Morgan Exchange-Traded Fund Tr… | 0.38% | 204,605 NS | July 31, 2026 | N-PORT |
| FTC · First Trust Exchange-Traded AlphaDE… | 0.37% | 56,826 NS | July 31, 2026 | N-PORT |
| IWR · iShares Trust | 0.36% | 2,336,086 SH | Sept. 11, 2026 | Daily |
| EGUS · iShares Trust | 0.36% | 1,132 SH | Sept. 11, 2026 | Daily |
| JOYT · J.P. Morgan Exchange-Traded Fund Tr… | 0.34% | 3,899 NS | July 31, 2026 | N-PORT |
| IMCB · iShares Trust | 0.34% | 64,965 SH | Sept. 11, 2026 | Daily |
| EVUS · iShares Trust | 0.30% | 13,166 SH | Sept. 11, 2026 | Daily |
| FFLG · FIDELITY COVINGTON TRUST | 0.28% | 19,459 NS | July 31, 2026 | N-PORT |
| XOEF · iShares Trust | 0.28% | 720 SH | Sept. 11, 2026 | Daily |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0.28% | 154,088 SH | Oct. 2, 2026 | Daily |
| ESUM · Strategy Shares | 0.27% | 5,627 NS | July 31, 2026 | N-PORT |
| WINN · Harbor ETF Trust | 0.24% | 31,833 NS | July 31, 2026 | N-PORT |
| DFLV · Dimensional ETF Trust | 0.24% | 188,776 NS | July 31, 2026 | N-PORT |
| CATH · Global X Funds | 0.24% | 35,583 NS | July 31, 2026 | N-PORT |
| HEQQ · J.P. Morgan Exchange-Traded Fund Tr… | 0.22% | 749 NS | July 31, 2026 | N-PORT |
| ESGU · iShares Trust | 0.20% | 421,118 SH | Sept. 11, 2026 | Daily |
| RSP · Invesco Exchange-Traded Fund Trust | 0.20% | 2,266,909 SH | Oct. 2, 2026 | Daily |
| USXF · iShares Trust | 0.20% | 34,234 SH | Sept. 11, 2026 | Daily |
| SIZE · iShares Trust | 0.20% | 9,721 SH | Sept. 11, 2026 | Daily |
| EUSA · iShares, Inc. | 0.19% | 42,285 SH | Sept. 11, 2026 | Daily |
| VTV · VANGUARD INDEX FUNDS | 0.19% | 5,470,146 SH | Aug. 19, 2026 | Daily |
| FAD · First Trust Exchange-Traded AlphaDE… | 0.18% | 12,350 NS | July 31, 2026 | N-PORT |
| DFUV · Dimensional ETF Trust | 0.18% | 327,155 NS | July 31, 2026 | N-PORT |
| FEX · First Trust Exchange-Traded AlphaDE… | 0.17% | 31,155 NS | July 31, 2026 | N-PORT |
| CHRI · Global X Funds | 0.15% | 140 NS | July 31, 2026 | N-PORT |
| ILCG · iShares Trust | 0.15% | 53,996 SH | Sept. 11, 2026 | Daily |
| QUAL · iShares Trust | 0.15% | 807,173 SH | Sept. 11, 2026 | Daily |
| IQSU · New York Life Investments ETF Trust | 0.15% | 5,623 NS | July 31, 2026 | N-PORT |
| SUSL · iShares Trust | 0.15% | 20,323 SH | Sept. 11, 2026 | Daily |
| ESLV · Strategy Shares | 0.14% | 236 NS | July 31, 2026 | N-PORT |
| DSI · iShares Trust | 0.14% | 87,882 SH | Sept. 11, 2026 | Daily |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0.14% | 344,148 SH | Aug. 19, 2026 | Daily |
| BSCS · Invesco Exchange-Traded Self-Indexe… | 0.14% | 4,863,000 | Oct. 2, 2026 | Daily |
| ACWV · iShares, Inc. | 0.14% | 52,593 SH | Sept. 11, 2026 | Daily |
| PFIG · Invesco Exchange-Traded Fund Trust … | 0.14% | 172,000 | Oct. 1, 2026 | Daily |
| IWD · iShares Trust | 0.13% | 1,266,618 SH | Sept. 11, 2026 | Daily |
| HAPI · Harbor ETF Trust | 0.13% | 7,541 NS | July 31, 2026 | N-PORT |
| AQLT · iShares Trust | 0.12% | 4,632 SH | Sept. 11, 2026 | Daily |
| GLBL · Pacer Funds Trust | 0.12% | 15 NS | July 31, 2026 | N-PORT |
| EGLE · Global X Funds | 0.11% | 29 NS | July 31, 2026 | N-PORT |
| VOOV · VANGUARD ADMIRAL FUNDS | 0.10% | 71,482 SH | Aug. 19, 2026 | Daily |
| QVML · Invesco Exchange-Traded Fund Trust … | 0.10% | 19,087 SH | Oct. 2, 2026 | Daily |
| USCL · iShares Trust | 0.09% | 30,549 SH | Sept. 11, 2026 | Daily |
| TOPC · iShares Trust | 0.09% | 349 SH | Sept. 11, 2026 | Daily |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0.09% | 8,633 SH | Oct. 2, 2026 | Daily |
| IVE · iShares Trust | 0.09% | 515,927 SH | Sept. 11, 2026 | Daily |
| ESMV · iShares Trust | 0.09% | 81 SH | Sept. 11, 2026 | Daily |
| LGDX · Tidal Trust III | 0.09% | 1,493 NS | July 31, 2026 | N-PORT |
| ESGV · VANGUARD WORLD FUND | 0.09% | 128,864 SH | Aug. 19, 2026 | Daily |
| ACVF · ETF Opportunities Trust | 0.09% | 1,589 NS | July 31, 2026 | N-PORT |
| DFSU · Dimensional ETF Trust | 0.09% | 22,900 NS | July 31, 2026 | N-PORT |
| XVV · iShares Trust | 0.09% | 6,682 SH | Sept. 11, 2026 | Daily |
| IUSV · iShares Trust | 0.09% | 271,422 SH | Sept. 11, 2026 | Daily |
| XRMI · Global X Funds | 0.08% | 475 NS | July 31, 2026 | N-PORT |
| VOO · VANGUARD INDEX FUNDS | 0.08% | 14,955,304 SH | Aug. 19, 2026 | Daily |
| VV · VANGUARD INDEX FUNDS | 0.08% | 672,462 SH | Aug. 19, 2026 | Daily |
| XYLG · Global X Funds | 0.08% | 591 NS | July 31, 2026 | N-PORT |
| XTR · Global X Funds | 0.08% | 44 NS | July 31, 2026 | N-PORT |
| PTLC · Pacer Funds Trust | 0.08% | 29,356 NS | July 31, 2026 | N-PORT |
| XYLD · Global X Funds | 0.08% | 28,920 NS | July 31, 2026 | N-PORT |
| IVV · iShares Trust | 0.08% | 7,257,429 SH | Sept. 11, 2026 | Daily |
| DFVX · Dimensional ETF Trust | 0.08% | 4,635 NS | July 31, 2026 | N-PORT |
| PRF · Invesco Exchange-Traded Fund Trust | 0.08% | 86,729 SH | Oct. 2, 2026 | Daily |
| PBP · Invesco Exchange-Traded Fund Trust | 0.08% | 3,428 SH | Oct. 2, 2026 | Daily |
| BKLC · BNY Mellon ETF Trust | 0.07% | 47,622 NS | July 31, 2026 | N-PORT |
| XCLR · Global X Funds | 0.07% | 31 NS | July 31, 2026 | N-PORT |
| PBUS · Invesco Exchange-Traded Fund Trust … | 0.07% | 99,747 SH | Oct. 2, 2026 | Daily |
| BBUS · J.P. Morgan Exchange-Traded Fund Tr… | 0.07% | 76,534 NS | July 31, 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.07% | 106,648 NS | July 31, 2026 | N-PORT |
| VOTE · TCW ETF Trust | 0.07% | 9,386 NS | July 31, 2026 | N-PORT |
| ILCB · iShares Trust | 0.07% | 10,752 SH | Sept. 11, 2026 | Daily |
| DFUS · Dimensional ETF Trust | 0.07% | 175,602 NS | July 31, 2026 | N-PORT |
| IYY · iShares Trust | 0.07% | 24,812 SH | Sept. 11, 2026 | Daily |
| VOXP · Advisors Series Trust | 0.07% | 48 NS | July 31, 2026 | N-PORT |
| SPUU · Direxion Shares ETF Trust | 0.07% | 2,173 NS | July 31, 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.07% | 27,431 NS | July 31, 2026 | N-PORT |
| IWB · iShares Trust | 0.07% | 393,450 SH | Sept. 11, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | 0.07% | 18,282,795 SH | Aug. 19, 2026 | Daily |
| VOOG · VANGUARD ADMIRAL FUNDS | 0.07% | 197,076 SH | Aug. 19, 2026 | Daily |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0.07% | 94,564 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.07% | 48,000 SH | Aug. 19, 2026 | Daily |
| QDPL · Pacer Funds Trust | 0.07% | 13,875 NS | July 31, 2026 | N-PORT |
| TOV · EA Series Trust | 0.07% | 2,241 NS | July 31, 2026 | N-PORT |
| ITOT · iShares Trust | 0.07% | 752,546 SH | Sept. 11, 2026 | Daily |
| IWV · iShares Trust | 0.07% | 156,590 SH | Sept. 11, 2026 | Daily |
| DFAC · Dimensional ETF Trust | 0.07% | 365,592 NS | July 31, 2026 | N-PORT |
| IVW · iShares Trust | 0.06% | 564,876 SH | Sept. 11, 2026 | Daily |
| IUS · Invesco Exchange-Traded Self-Indexe… | 0.06% | 7,296 SH | Oct. 2, 2026 | Daily |
| PHDG · Invesco Actively Managed Exchange-T… | 0.06% | 446 SH | Oct. 2, 2026 | Daily |
| IUSG · iShares Trust | 0.06% | 232,595 SH | Sept. 11, 2026 | Daily |
| HCMT · Direxion Shares ETF Trust | 0.06% | 4,008 NS | July 31, 2026 | N-PORT |
| TOK · iShares Trust | 0.06% | 1,613 SH | Sept. 11, 2026 | Daily |
| SPXL · Direxion Shares ETF Trust | 0.06% | 45,012 NS | July 31, 2026 | N-PORT |
| URTH · iShares, Inc. | 0.06% | 52,555 SH | Sept. 11, 2026 | Daily |
| TILT · FlexShares Trust | 0.05% | 13,604 NS | July 31, 2026 | N-PORT |
| ACWI · iShares Trust | 0.05% | 184,834 SH | Sept. 11, 2026 | Daily |
| ROUS · Lattice Strategies Trust | 0.04% | 3,407 NS | July 31, 2026 | N-PORT |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.04% | 480,405 SH | Aug. 19, 2026 | Daily |
| CRBN · iShares Trust | 0.04% | 4,703 SH | Sept. 11, 2026 | Daily |
| RWL · Invesco Exchange-Traded Fund Trust … | 0.03% | 37,719 SH | Oct. 2, 2026 | Daily |
| DXUV · Dimensional ETF Trust | 0.03% | 1,805 NS | July 31, 2026 | N-PORT |
| PEVC · Pacer Funds Trust | 0.01% | 2 NS | July 31, 2026 | N-PORT |
| BSV · VANGUARD BOND INDEX FUNDS | · | · | July 15, 2026 | Daily |
| BND · VANGUARD BOND INDEX FUNDS | · | · | July 15, 2026 | Daily |
| VCSH · VANGUARD SCOTTSDALE FUNDS | · | · | July 15, 2026 | Daily |
| BNDW · VANGUARD SCOTTSDALE FUNDS | · | · | July 14, 2026 | Daily |
EW Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 40 analysts
BUY
Median target
$101.50
+19.2%
13 32.5%
Strong Buy
18 45.0%
Buy
9 22.5%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
26 analysts · 2026-09-30Mean target $100.96 +18.6%
Now
Current price $85.15
Low$84.00
Mean$100.96
High$110.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| EW | $49.50B | 46.6 | 11.6% | 17.7% | 10.6% | 78.0% |
| ABT | $250.18B | 33.7 | 5.7% | 14.7% | 13.1% | · |
| ISRG | $201.11B | 72.0 | 20.5% | 28.4% | 16.7% | 66.0% |
| SYK | $134.44B | 41.8 | 11.2% | 12.9% | 15.1% | 64.0% |
| BSX | · | 49.1 | 19.9% | 14.4% | 12.6% | 69.0% |
| BDX | · | 25.3 | 8.2% | 7.7% | 6.5% | · |
| IDXX | $53.93B | 51.7 | 10.4% | 24.6% | 69.2% | 61.8% |
| DXCM | $25.54B | 31.8 | 15.6% | 17.9% | 31.4% | 60.1% |
| RMD | $28.11B | 18.7 | 9.8% | 26.9% | 23.6% | 61.1% |
| GEHC | · | 18.0 | 4.8% | 10.1% | 22.1% | 40.0% |
| ZBH | $28.66B | 25.3 | 7.2% | 8.6% | 5.6% | · |
Trading Signals Recent buy/sell signals with entry price and risk/reward ratio
No open signal right now — no card is filled, and that's honest.
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 4, 2026